Please provide your email address to receive an email when new articles are posted on . Results from a pilot randomized controlled trial showed Thalomid induced and maintained clinical remission in ...

Summit-based Celgene was accused of promoting its cancer drug Thalomid and related compound Revlimid for uses not approved by U.S. regulators in a newly unsealed lawsuit filed by a former saleswoman.

Celgene thanked the woman who had the idea to use thalidomide as a treatment for multiple myeloma in its annual report, but says she isn't owed a dime for discovering the $2.2 billion-a-year treatment ...

A federal judge seems to be suggesting that Celgene (CELG) should settle a widow's lawsuit -- one in which the woman accused the company of not compensating her for discovering that Thalomid ...

Drugs can be like the stars. Some shine brightly. Some appear seemingly out of nowhere. And some grow dimmer over time and eventually disappear from the night sky. A star is bornThalomid, then known ...

A new study shows that Thalomid, from Celgene , can triple the amount of time patients with the blood cancer multiple myeloma can live without their disease worsening. The study is a victory for ...

A new study demonstrates that Celgene's Thalomid can triple the time multiple myeloma patients can live without seeing the disease progress. Once notorious for causing birth defects, Thalomid--often ...

Shares of Celgene were buoyed in overnight trading by news that the FDA had approved Thalomid as a therapy for the blood cancer multiple myeloma. Thalomid had originally been approved for leprosy but ...

In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myeloma. She spent her nights reading medical journals at his bedside and her days ...

BOSTON (Reuters) - The chief operating officer of Celgene Corp. said on Thursday he expects sales of the company's new cancer drug Revlimid to surpass sales of its older Thalomid treatment, but said ...

Celgene Corp. was accused of promoting its cancer drug Thalomid and related compound Revlimid for uses not approved by U.S. regulators in a newly unsealed lawsuit filed by a former saleswoman.